SCHEMBL4716303

SCHEMBL4716303

O=C(COCc1cc(S(=O)(=O)N2CCCCC2)ccc1Cl)c1ccncc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
ALDH1A1 P00352 6/20 0.49
KDM4E B2RXH2 1/20 0.49
NPC1 O15118 1/20 0.49
LMNA P02545 2/20 0.48
MAPT P10636 5/20 0.48
TSHR P16473 3/20 0.47
NPSR1 Q6W5P4 1/20 0.47
POLB P06746 1/20 0.46
ATM Q13315 1/20 0.45
AGTR1 P30556 1/20 0.45
USP2 O75604 2/20 0.45
MAPK1 P28482 2/20 0.45
GAA P10253 1/20 0.45
HTT P42858 1/20 0.45
MCOLN3 Q8TDD5 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4716188 0.89 AGTR1 (0.53) MEN1KMT2AALDH1A1NPC1MAPT
SCHEMBL4715768 0.88 MAPT (0.56) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL4716103 0.84 MEN1 (0.51) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL4713433 0.84 SMN1; SMN2 (0.54) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL4713545 0.83 TSHR (0.57) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL4714267 0.83 TSHR (0.54) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL4713091 0.83 ALDH1A1 (0.54) MEN1KMT2AALDH1A1KDM4ENPC1
SCHEMBL4716298 0.83 MCOLN3 (0.54) MEN1KMT2AALDH1A1MAPTTSHR
SCHEMBL4762292 0.82 MAPK1 (0.58) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL4716672 0.82 CNR1 (0.44) KMT2AALDH1A1NPC1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615904-B1 SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS ASTRAZENECA AB (SE) 2008-02-27 EP claimed
US-20070021606-A1 Therapeutic compounds ASTRAZENECA AB (SE) 2007-01-25 US claimed
EP-1615904-B1 SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS ASTRAZENECA AB (SE) 2008-02-27 EP disclosed
US-20070021606-A1 Therapeutic compounds ASTRAZENECA AB (SE) 2007-01-25 US disclosed
US-20070021606-A1 Therapeutic compounds ASTRAZENECA AB (SE) 2007-01-25 US disclosed
US-20070021606-A1 Therapeutic compounds ASTRAZENECA AB (SE) 2007-01-25 US disclosed
EP-1615904-A2 SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS AstraZeneca AB (SE) 2006-01-18 EP disclosed
WO-2004092135-A2 SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS ASTRAZENECA (SE) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021606-A1 Therapeutic compounds GRIN1, GRIN3A, GRM2 MEN1 4633/4885KMT2A 3726/4885ALDH1A1 1721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.